An Improved Manufacturing Process for a Recombinant Polyprotein Vaccine - Combating the devastating global disease of leishmaniasis with a new therapeutic and prophylactic vaccine - BioPharm


An Improved Manufacturing Process for a Recombinant Polyprotein Vaccine
Combating the devastating global disease of leishmaniasis with a new therapeutic and prophylactic vaccine

BioPharm International

Immunogenicity Assay

Figure 3
Female BALB/c (Bagg albino color locus genotype c/c) mice were purchased from Charles River Laboratories (Wilmington, MA) and were maintained in specific-pathogen-free conditions. Eight- to 12-week-old mice at the beginning of experiments were used. Three mice per group were immunized with 10 g of Leish-110f or Leish-111f formulated with 20 g of an adjuvant MPL-SE (GlaxoSmithKline Biologicals, Rixensant, Belgium) in a volume of 0.1 mL. The mice were immunized subcutaneously once at the base of the tail. Blood was taken from the mice one week after the immunization to determine immunoglobulin G1 (IgG1) and immunoglobulin G2a (IgG2a) antibody titers. Plates were coated with 200 ng per well of Leish-110f or Leish-111f diluted in coating buffer, followed by blocking with phosphate-buffered saline containing 0.05% Tween 20 and 1% bovine serum albumin. Mouse serum samples were diluted to 1:100 and applied to the plates in two-fold serial dilutions. The plates were incubated with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG1 or IgG2a (SouthernBiotech, Birmingham, AL), were developed with 3,3',5,5'-Tetramethylbenzidine (TMB) substrate, and were read by a microplate reader at a 450 nanometer wavelength. Endpoint titers were calculated with GraphPad Prism software using an optical density (OD) value of 0.1 as a cutoff.


Protein Production

Figure 4
The fed-batch fermentation of the HMS-174/L110f recombinant system was consistent in its growth profile and production of the vaccine product Leish-110f. The Leish-110f protein was produced in the inclusion bodies. A two-step orthogonal purification procedure post-inclusion body washing achieved significant purification of the vaccine candidate. A chromatogram of the QFF anion exchange column separation (Figure 3) shows a single major peak that contained the Leish-110f polyprotein. The second step in the purification used ceramic hydroxyapatite, with the Leish-110f protein eluted as a single major peak (Figure 4) at low concentrations of phosphate. The majority of the contaminants remained bound to the resins used. The in-process SDS-PAGE gel shown in Figure 5 illustrates purification as additional purification steps were added. The utility of coupling these methods is that the eluted protein from the first step need not be conditioned between chromatographies, as the protein binds to the hydroxyapatite even in the presence of NaCl. SDS-PAGE of the eluted material illustrates the purity of the final Leish-110f protein product (Figure 6). Yield of purified protein is more than 150 mg/L and is a tremendous improvement over the original L-111f protein yield of 30 mg/L.

Figure 5
Following purification, urea was removed by diafiltration, and the protein was filled and lyophilized as described in the materials and methods section, above. The protein formed a stable white cake in the vials after lyophilization, and that quickly redissolved upon addition of water. Real-time stability studies at several temperatures are ongoing, but preliminary data suggests that the purified bulk protein and the lyophilized cake are stable at all temperatures tested (data not shown).

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here